Amphastar Pharmaceuticals Inc
NASDAQ:AMPH

Watchlist Manager
Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Watchlist
Price: 29.4 USD 5.98% Market Closed
Market Cap: 1.4B USD
Section:
 

Relative Value

The Relative Value of one AMPH stock under the Base Case scenario is 53.82 USD. Compared to the current market price of 29.4 USD, Amphastar Pharmaceuticals Inc is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMPH Relative Value
Base Case
53.82 USD
Undervaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
85
vs Industry
54
Median 3Y
3
Median 5Y
2.8
Industry
2.7
Forward
1.8
More Details
12.2
P/E
P/E
Price to Earnings
12.2
vs History
76
vs Industry
40
Median 3Y
13.9
Median 5Y
18.7
Industry
21.6
Forward
8.4
More Details
8.9
P/OCF
P/OCF
Price to OCF
8.9
vs History
79
vs Industry
45
Median 3Y
10.7
Median 5Y
12.2
Industry
16.9
More Details
13.3
P/FCFE
P/FCFE
Price to FCFE
13.3
vs History
47
vs Industry
32
Median 3Y
9.9
Median 5Y
12.5
Industry
22.9
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
85
vs Industry
41
Median 3Y
3
Median 5Y
2.7
Industry
2.3
More Details
2.3
EV/S
EV/S
Enterprise Value to Sales
2.3
vs History
76
vs Industry
44
Median 3Y
3.3
Median 5Y
2.8
Industry
3
Forward
2.2
More Details
4.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.7
vs History
85
vs Industry
43
Median 3Y
6.3
Median 5Y
5.8
Industry
5.6
More Details
8.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.4
vs History
77
vs Industry
42
Median 3Y
9.4
Median 5Y
11.7
Industry
13.4
Forward
6.1
More Details
11.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.3
vs History
74
vs Industry
40
Median 3Y
11.6
Median 5Y
14.5
Industry
16.7
Forward
7
More Details
10.6
EV/OCF
EV/OCF
Enterprise Value to OCF
10.6
vs History
73
vs Industry
42
Median 3Y
12.2
Median 5Y
12.2
Industry
16.1
More Details
15.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.3
vs History
74
vs Industry
32
Median 3Y
15.1
Median 5Y
17.1
Industry
18.9
More Details
1.3
EV/IC
EV/IC
Enterprise Value to IC
1.3
vs History
85
vs Industry
48
Median 3Y
2
Median 5Y
2
Industry
2
More Details

Multiples Across Competitors

AMPH Competitors Multiples
Amphastar Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
1.4B USD 1.9 12.2 8.4 11.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
504.6B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
272.7B CHF 4.4 28.9 12.3 14.4
UK
AstraZeneca PLC
LSE:AZN
219B GBP 5.1 31.4 109.4 160.1
US
Merck & Co Inc
NYSE:MRK
271.6B USD 4.2 14.3 10.1 12
CH
Novartis AG
SIX:NOVN
218.4B CHF 4.9 19 12 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.2 11.3 13.1
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Average P/E: 23.6
12.2
5%
2.4
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Average EV/EBITDA: 400.9
8.4
1%
8.4
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
109.4
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Average EV/EBIT: 1 713.6
11.3
7%
1.6
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.4
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
160.1
23%
7
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
AMPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMPH stock valuation using valuation multiples.
Wall Street Estimates
AMPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.